Aspirin/Pravastatin Stronger In Combination For CHD Secondary Prevention
This article was originally published in The Tan Sheet
Executive Summary
A combination of aspirin with the cholesterol-lowering drug pravastatin is 92% likely to provide a synergistic effect in secondary prevention of myocardial infarction, according to research published in the Jan. 12 Archives of Internal Medicine
You may also be interested in...
Pravachol OTC Label Studies, Redefined Population Urged By Cmte.
Bristol-Myers Squibb's Pravachol (pravastatin) 10 mg is an attractive candidate for OTC status, but the company should first conduct additional label comprehension studies and better define the target population for the cholesterol agent, FDA advisory committee members suggested July 14.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands